Search

Displaying results 5091 - 5100 of 10000 in total
  1. Drug

    Velaglucerase alfa

    go.drugbank.com/drugs/DB06720
    Approved

    Additionally, Velaglucerase alfa has also been investigated for use in Type 3 Gaucher disease. … Velaglucerase alfa is a gene-activated human recombinant glucocerebrosidase used for the treatment of Type 1 Gaucher disease, caused by a deficiency of the lysosomal enzyme glucocerebrosidase.

  2. Drug

    Prolectin-M

    go.drugbank.com/drugs/DB16521
    Investigational

    [L31343] It is being investigated in the clinical trial NCT04512027 (Prolectin-M in COVID-19 Patients Having Mild to Moderate Symptoms Not Requiring Oxygen Support. (Prolectin-M)). … Prolectin-M is a (1-6)-alpha-D-mannopyranose[L31338] and acts as an antagonist of galectin.

  3. Drug

    OPC-28326

    go.drugbank.com/drugs/DB05461
    Experimental

    It is the only clinical compound with this profile. It is currently being investigated in the treatment of peripheral vascular diseases and Raynaud's syndrome. … At low doses, OPC 28326 selectively vasodilates the femoral arterial bed due to its inhibitory action at alpha-2-adrenoceptors while having minimal action on systemic blood pressure, heart rate and coronary

  4. Drug

    BG-777

    go.drugbank.com/drugs/DB05839
    Experimental

    BG-777 is an immunomodulator with proven efficacy against viral and bacterial infections in preclinical studies.

  5. Drug

    Sapacitabine

    go.drugbank.com/drugs/DB06365
    Investigational

  6. Drug

    Epoetin delta

    go.drugbank.com/drugs/DB11624
    ApprovedWithdrawn

    Epoetin Delta is an ingredient in the EMA-withdrawn product Dynepo.

  7. Drug

    Binodenoson

    go.drugbank.com/drugs/DB04853
    Investigational

    This specificity allows Binodenoson to deliver - in a single injection - a more effective dose of medication with fewer side effects than current treatments, which typically require a 15-20 minute infusion … Binodenoson is a pharmacologic stress agent specific to the only adenosine receptor necessary for increased cardiac blood flow, the A<sub>2A</sub> receptor.

  8. Drug

    ICX-RHY

    go.drugbank.com/drugs/DB05716
    Experimental

    The drug was under investigation in clinical trials in the UK for the treatment of skin erosions in recessive dystrophic epidermolysis bulllosa. … ICX-RHY is an investigational therapy comprised of cultured allogeneic fibroblasts.

  9. Drug

    Astaxanthin

    go.drugbank.com/drugs/DB06543
    Investigational

    It may be found in fish feed or some animal food as a color additive. … Astaxanthin is a keto-carotenoid in the terpenes class of chemical compounds. It is classified as a xanthophyll but it is a carotenoid with no vitamin A activity.

  10. Drug

    NCX 1015

    go.drugbank.com/drugs/DB05825
    Experimental

    NCX 1015 is nitric oxide-releasing derivative of prednisolone developed for the treatment of inflammatory bowel disease (IBD) by NicOx SA.